Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-β induced retinal pigmented epithelium degeneration

• Published in: Signal transduction and targeted therapy Vol. 6; no. 1; p. 149
• Main Authors: Narendran, Siddharth, Pereira, Felipe, Yerramothu, Praveen, Apicella, Ivana, Wang, Shao-bin, Ambati, Kameshwari, Hirahara, Shuichiro, Kim, Younghee, Ambati, Meenakshi, Ambati, Vidya L., Huang, Peirong, Varshney, Akhil, Nagasaka, Yosuke, Fukuda, Shinichi, Baker, Kirstie L., Marion, Kenneth M., Deussing, Jan M., Sadda, Srinivas R., Gelfand, Bradley D., Ambati, Jayakrishna
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 14.04.2021; Nature Publishing Group
• Subjects: 631/250/262; 692/308/575; Amyloid beta-Peptides - genetics; Amyloid beta-Peptides - metabolism; Animals; Cancer Research; Cell Biology; Disease Models, Animal; Humans; Internal Medicine; Macular degeneration; Macular Degeneration - drug therapy; Macular Degeneration - genetics; Macular Degeneration - metabolism; Male; Medicine; Medicine & Public Health; Mice; Mice, Knockout; Oncology; Pathology; Retinal Pigment Epithelium - metabolism; Reverse Transcriptase Inhibitors - pharmacology

Nonfibrillar amyloid-β oligomers (AβOs) are a major component of drusen, the sub-retinal pigmented epithelium (RPE) extracellular deposits characteristic of age-related macular degeneration (AMD), a common cause of global blindness. We report that AβOs induce RPE degeneration, a clinical hallmark of...